



# PHILIPPINE RHEUMATOLOGY ASSOCIATION

## *19<sup>th</sup> Annual Meeting*

February 2-4, 2012

Manila Peninsula Hotel, Makati City

Theme: "Braving the Challenges: Rheumatology 2012"

### RESEARCH COMMITTEE

#### **Instructions for Submitting an Abstract:**

1. Submit original abstract along with (5) photocopies to the Research Committee c/o PRA SECRETARIAT or email: pra\_office@yahoo.com
2. The content of the paper must focus on a rheumatology topic.
3. Try not to exceed 325 words.
4. Use standard abbreviations (spell out in full at first mention, add abbreviations in parenthesis). Use numerals for numbers.
5. Organize body of abstract using headings and information described in the sample given.
6. Closing date for submission of abstract: **5:00pm on 07 January 2012**  
IMPORTANT: Papers accepted for presentation in the free communication sessions must be presented as scheduled. Presenters who for justifiable reasons are unable to present, MUST formally withdraw in writing to the Scientific Committee.
7. Indicate the required information on the authors as follows:

**Name of Author/s:** \_\_\_\_\_

**Name of Presenter:** \_\_\_\_\_

**Institution:** \_\_\_\_\_

**Tel. No.:** \_\_\_\_\_ **Fax No.:** \_\_\_\_\_

## **ABSTRACT CONTENTS**

### **CAPITALIZE ENTIRE ABSTRACT TITLE.**

Authors. Underline the presenting author's name.

Institution, City.

**OBJECTIVES:** State main question or study objective(s) or hypothesis.

**DESIGN:** Describe study design and temporal direction (retrospective or prospective). For trials, indicated if randomized or blinded.

**SETTING:** Indicate the study setting (hospital, clinic, and community). Also include the level of clinical care (primary or tertiary) (private practice or institutional).

**PATIENTS/PARTICIPANTS:** State selection procedures, entry criteria and numbers of participants entering and finishing the study.

**INTERVENTIONS IF ANY:** Describe the essential features of any interventions/exposure, including their method and duration of administration.

**MAIN OUTCOME MEASURE(S):** The primary study outcome measures should be indicated as planned before the data collection began.

**RESULTS:** Describe measurements that are not evident from the nature of the main results and indicate any blinding. If possible, the results should be accompanied by confidence intervals (most often the 95% interval) and the exact level of statistical significance. For comparative studies, confidence intervals should relate to the differences between groups. Absolute values should be indicated when risk changes or effect sizes are given.

**CONCLUSION:** State only those conclusions of the study that are directly supported by data, along with their clinical application (avoiding generalization) or whether additional study is required before the information could be used in usual clinical settings.

**RESEARCH FUNDING:** ex PCHRD, WHO, etc.